Home LiteratureArticle Details
PMID: 22623042 Published · ppublish English Journal Article

Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Digestive diseases and sciences ·Vol. 57 ·No. 11 ·2012-11-00 ·Pages 2955-64

Nemoto H, Kataoka K, Ishikawa H, Ikata K, Arimochi H, Iwasaki T, Ohnishi Y, Kuwahara T, Yasutomo K

Abstract

Clinical observations and experimental colitis models have indicated the importance of intestinal bacteria in the etiology of ulcerative colitis (UC), but a causative bacterial agent has not been identified. To determine how intestinal bacteria are associated with UC, fecal microbiota and other components were compared for UC patients and healthy adults. Fresh feces were collected from 48 UC patients. Fecal microbiota were analyzed by use of terminal-restriction fragment length polymorphism (T-RFLP), real-time PCR, and culture. The concentrations of organic acids, indole, and ammonia, and pH and moisture, which are indicators of the intestinal environment, were measured and compared with healthy control data. T-RFLP data divided the UC patients into four clusters; one cluster was obtained for healthy subjects. The diversity of fecal microbiota was significantly lower in UC patients. There were significantly fewer Bacteroides and Clostridium subcluster XIVab, and the amount of Enterococcus was higher in UC patients than in healthy subjects. The fecal concentration of organic acids was significantly lower in UC patients who were in remission. UC patients have imbalances in the intestinal environment-less diversity of fecal microbiota, lower levels of major anaerobic bacteria (Bacteroides and Clostridium subcluster XIVab), and a lower concentration of organic acids.

MeSH Terms
Adult Aged Bacteria/isolation & purification Case-Control Studies Colitis, Ulcerative/microbiology DNA, Bacterial/analysis Feces/microbiology Female Humans Intestinal Mucosa/microbiology Male Middle Aged Polymorphism, Restriction Fragment Length Real-Time Polymerase Chain Reaction Statistics, Nonparametric
Chemicals
DNA, Bacterial
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Nemoto Hideyuki
Department of Immunology and Parasitology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8503, Japan. nemoto@genmaikoso.co.jp
Kataoka Keiko
Ishikawa Hideki
Ikata Kazue
Arimochi Hideki
Iwasaki Teruaki
Ohnishi Yoshinari
Kuwahara Tomomi
Yasutomo Koji
References (57)
57 references, click to expand
  1. Real-time PCR quantitation of clostridia in feces of autistic children.
    Appl Environ Microbiol. 2004 Nov;70(11):6459-65 PMID: 15528506
  2. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.
    Gut. 2000 Jan;46(1):64-72 PMID: 10601057
  3. Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces.
    Appl Environ Microbiol. 2002 Nov;68(11):5445-51 PMID: 12406736
  4. Rapid and noninvasive metabonomic characterization of inflammatory bowel disease.
    J Proteome Res. 2007 Feb;6(2):546-51 PMID: 17269711
  5. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes.
    Life Sci. 2003 Aug 15;73(13):1683-90 PMID: 12875900
  6. Commensal host-bacterial relationships in the gut.
    Science. 2001 May 11;292(5519):1115-8 PMID: 11352068
  7. Enterococcus faecalis strains differentially regulate Alix/AIP1 protein expression and ERK 1/2 activation in intestinal epithelial cells in the context of chronic experimental colitis.
    J Proteome Res. 2009 Mar;8(3):1183-92 PMID: 19166300
  8. Immune adaptations that maintain homeostasis with the intestinal microbiota.
    Nat Rev Immunol. 2010 Mar;10(3):159-69 PMID: 20182457
  9. On the action of 5-amino-salicylic acid and sulfapyridine on M. avium including subspecies paratuberculosis.
    PLoS One. 2007 Jun 13;2(6):e516 PMID: 17565369
  10. Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease.
    Int J Med Microbiol. 2008 Jul;298(5-6):463-72 PMID: 17897884
  11. Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody.
    J Gastroenterol Hepatol. 2002 Aug;17(8):849-53 PMID: 12164960
  12. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea.
    J Clin Gastroenterol. 2010 May-Jun;44(5):354-60 PMID: 20048681
  13. Cyclosporine in severe ulcerative colitis refractory to steroid therapy.
    N Engl J Med. 1994 Jun 30;330(26):1841-5 PMID: 8196726
  14. Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission.
    Am J Gastroenterol. 2008 Mar;103(3):643-8 PMID: 18341488
  15. Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut.
    Appl Environ Microbiol. 1999 Nov;65(11):4799-807 PMID: 10543789
  16. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis.
    PLoS One. 2008 Jun 25;3(6):e2496 PMID: 18575598
  17. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.
    J Am Coll Nutr. 2003 Feb;22(1):56-63 PMID: 12569115
  18. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice.
    Am J Pathol. 2002 Jun;160(6):2253-7 PMID: 12057927
  19. Towards the human intestinal microbiota phylogenetic core.
    Environ Microbiol. 2009 Oct;11(10):2574-84 PMID: 19601958
  20. Intestinal TM7 bacterial phylogenies in active inflammatory bowel disease.
    J Med Microbiol. 2008 Dec;57(Pt 12):1569-1576 PMID: 19018031
  21. Treatment of ulcerative colitis using fecal bacteriotherapy.
    J Clin Gastroenterol. 2003 Jul;37(1):42-7 PMID: 12811208
  22. [Improved methodology of qualitative and quantitative analysis of the intestinal flora of man and animals].
    Zentralbl Bakteriol Orig. 1965 Mar;195(4):455-69 PMID: 5860078
  23. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides.
    Physiol Rev. 2001 Jul;81(3):1031-64 PMID: 11427691
  24. Effects of fermented brown rice on the intestinal environments in healthy adult.
    J Med Invest. 2011 Aug;58(3-4):235-45 PMID: 21921425
  25. Influence of dietary protein supplements on the formation of bacterial metabolites in the colon.
    Gut. 1997 Jul;41(1):70-6 PMID: 9274475
  26. Development of Bacteroides 16S rRNA gene TaqMan-based real-time PCR assays for estimation of total, human, and bovine fecal pollution in water.
    Appl Environ Microbiol. 2006 Jun;72(6):4214-24 PMID: 16751534
  27. Lactate is mainly fermented to butyrate by human intestinal microfloras but inter-individual variation is evident.
    J Appl Microbiol. 2005;99(1):201-12 PMID: 15960680
  28. Development of an extensive set of 16S rDNA-targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real-time PCR.
    J Appl Microbiol. 2004;97(6):1166-77 PMID: 15546407
  29. Prevalence of ulcerative colitis and Crohn's disease in Japan.
    J Gastroenterol. 2009;44(7):659-65 PMID: 19424654
  30. A genome-wide association study identifies three new susceptibility loci for ulcerative colitis in the Japanese population.
    Nat Genet. 2009 Dec;41(12):1325-9 PMID: 19915573
  31. Rationale for the luminal provision of butyrate in intestinal diseases.
    Eur J Nutr. 2000 Aug;39(4):164-71 PMID: 11079736
  32. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis.
    Scand J Gastroenterol. 2009;44(2):180-6 PMID: 18825588
  33. The human intestinal microbiome: a new frontier of human biology.
    DNA Res. 2009 Feb;16(1):1-12 PMID: 19147530
  34. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis.
    Aliment Pharmacol Ther. 2004 Nov 15;20(10):1133-41 PMID: 15569116
  35. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach.
    Gut. 2006 Feb;55(2):205-11 PMID: 16188921
  36. Effects of amino acid-derived luminal metabolites on the colonic epithelium and physiopathological consequences.
    Amino Acids. 2007 Nov;33(4):547-62 PMID: 17146590
  37. In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
    Anaerobe. 2004 Aug;10(4):205-11 PMID: 16701520
  38. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria.
    Gastroenterology. 2005 Apr;128(4):891-906 PMID: 15825073
  39. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial.
    Gut. 2005 Feb;54(2):242-9 PMID: 15647189
  40. Microbes in gastrointestinal health and disease.
    Gastroenterology. 2009 Jan;136(1):65-80 PMID: 19026645
  41. Review article: the role of butyrate on colonic function.
    Aliment Pharmacol Ther. 2008 Jan 15;27(2):104-19 PMID: 17973645
  42. Hydrogen sulphide: a bacterial toxin in ulcerative colitis?
    Gut. 1996 Jul;39(1):1-4 PMID: 8881797
  43. Interleukin-10-deficient mice develop chronic enterocolitis.
    Cell. 1993 Oct 22;75(2):263-74 PMID: 8402911
  44. Characterization of antibody responses against rectal mucosa-associated bacterial flora in patients with ulcerative colitis.
    J Gastroenterol Hepatol. 2000 Jan;15(1):61-8 PMID: 10719749
  45. Terminal restriction fragment length polymorphism analysis of the diversity of fecal microbiota in patients with ulcerative colitis.
    Inflamm Bowel Dis. 2007 Aug;13(8):955-62 PMID: 17455205
  46. Mucosa-associated bacteria in ulcerative colitis before and after antibiotic combination therapy.
    Aliment Pharmacol Ther. 2005 Apr 15;21(8):1017-27 PMID: 15813838
  47. Understanding the effects of diet on bacterial metabolism in the large intestine.
    J Appl Microbiol. 2007 May;102(5):1197-208 PMID: 17448155
  48. Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives.
    Gut. 2011 May;60(5):631-7 PMID: 21209126
  49. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice.
    Gastroenterology. 2003 Jul;125(1):162-77 PMID: 12851881
  50. Psychological stress in IBD: new insights into pathogenic and therapeutic implications.
    Gut. 2005 Oct;54(10):1481-91 PMID: 16162953
  51. Identification and quantitation of mucosal and faecal desulfovibrios using real time polymerase chain reaction.
    Gut. 2004 Apr;53(4):523-9 PMID: 15016746
  52. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis.
    Br J Surg. 2009 Feb;96(2):151-8 PMID: 19160346
  53. Coordination of tolerogenic immune responses by the commensal microbiota.
    J Autoimmun. 2010 May;34(3):J220-5 PMID: 19963349
  54. The gut microbiota shapes intestinal immune responses during health and disease.
    Nat Rev Immunol. 2009 May;9(5):313-23 PMID: 19343057
  55. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region.
    Nat Genet. 2009 Dec;41(12):1330-4 PMID: 19915572
  56. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene.
    Cell. 1993 Oct 22;75(2):253-61 PMID: 8402910
  57. Terminal restriction fragment length polymorphism analysis for human fecal microbiota and its application for analysis of complex bifidobacterial communities.
    Microbiol Immunol. 2003;47(2):133-42 PMID: 12680716
Article Info
Journal
Digestive diseases and sciences
Abbr.
Dig Dis Sci
ISSN
1573-2568
Published
2012-11-00
Epub
2012-00-24
Pages
2955-64
Language
English
Region
United States
NLM ID
7902782
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com